Abbott signs seven-year deal with Premier:
This article was originally published in Clinica
Abbott Laboratories has signed a seven-year "multi-billion" dollar contract with Premier, the Charlotte, North Carolina-based hospital purchasing group. The contract extends a previous agreement, which covered items such as imaging agents, and areas including critical care and immunochemistry. The new terms also include patient-controlled analgesia, haematology and anaesthesia trays.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.